EP1789451A4 - Protéines de liaison au complexe tie - Google Patents

Protéines de liaison au complexe tie

Info

Publication number
EP1789451A4
EP1789451A4 EP05784935A EP05784935A EP1789451A4 EP 1789451 A4 EP1789451 A4 EP 1789451A4 EP 05784935 A EP05784935 A EP 05784935A EP 05784935 A EP05784935 A EP 05784935A EP 1789451 A4 EP1789451 A4 EP 1789451A4
Authority
EP
European Patent Office
Prior art keywords
binding proteins
complex binding
tie complex
tie
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05784935A
Other languages
German (de)
English (en)
Other versions
EP1789451A2 (fr
Inventor
Clive R Wood
Daniel T Dransfield
Henk Pieters
Rene Hoet
Simon E Hufton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/026116 external-priority patent/WO2005019267A2/fr
Priority claimed from US11/049,536 external-priority patent/US7871610B2/en
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of EP1789451A2 publication Critical patent/EP1789451A2/fr
Publication of EP1789451A4 publication Critical patent/EP1789451A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05784935A 2004-08-12 2005-08-09 Protéines de liaison au complexe tie Withdrawn EP1789451A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2004/026116 WO2005019267A2 (fr) 2003-08-12 2004-08-12 Ligands se fixant au tie 1
US10/916,840 US7348001B2 (en) 2003-08-12 2004-08-12 Tie1-binding ligands
US11/049,536 US7871610B2 (en) 2003-08-12 2005-02-02 Antibodies to Tie1 ectodomain
PCT/US2005/028413 WO2006020706A2 (fr) 2004-08-12 2005-08-09 Proteines de liaison au complexe tie

Publications (2)

Publication Number Publication Date
EP1789451A2 EP1789451A2 (fr) 2007-05-30
EP1789451A4 true EP1789451A4 (fr) 2009-12-02

Family

ID=35908119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05784935A Withdrawn EP1789451A4 (fr) 2004-08-12 2005-08-09 Protéines de liaison au complexe tie

Country Status (5)

Country Link
EP (1) EP1789451A4 (fr)
JP (1) JP2008532476A (fr)
AU (1) AU2005272848A1 (fr)
CA (1) CA2576886A1 (fr)
WO (1) WO2006020706A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2377936A3 (fr) * 2005-03-25 2012-06-13 National Research Council of Canada Procédé d'isolation de polypeptides solubles
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
CA2635588C (fr) 2005-12-30 2015-11-10 Dyax Corp. Proteines de liaison a la metalloproteinase
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
EA200900562A1 (ru) * 2006-10-17 2009-10-30 Дайэкс Корп. Способ лечения расстройства, связанного с ангиогенезом
EP2647388A1 (fr) * 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Anticorps dirigés contre l'ERBB3 et leurs utilisations
EP2036980A1 (fr) * 2007-09-14 2009-03-18 Gruber, Jens Dérégulation de l'expression génétique à l'aide de particules semblables à un virus chargées d'acide nucléique
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
PE20120015A1 (es) 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
US20120114667A1 (en) * 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
US9017670B2 (en) * 2011-08-19 2015-04-28 Regeneron Pharmaceuticals, Inc. Anti-Tie2 antibodies and uses thereof
EP2968541A4 (fr) 2013-03-15 2017-02-08 Zyngenia, Inc. Complexes multispécifiques multivalents et monovalents et leurs utilisations
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
EP3081575A1 (fr) * 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anticorps anti-plasmodium pour parasite
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2022199603A1 (fr) * 2021-03-25 2022-09-29 Nanjing GenScript Biotech Co., Ltd. Protéines de fusion d'anticorps et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO2005019267A2 (fr) * 2003-08-12 2005-03-03 Dyax Corp. Ligands se fixant au tie 1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO2005019267A2 (fr) * 2003-08-12 2005-03-03 Dyax Corp. Ligands se fixant au tie 1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DRANSFIELD: "Targeting tie1 inhibits the growth of tumor xenografts as a monotherapy and has increased activity in combination with a VEGF inhibitor", EUROPEAN JOURNAL OF CANCER SUPPLEMENTS, vol. 4, no. 12, 28 September 2004 (2004-09-28), XP002550532, Retrieved from the Internet <URL:http://ex2.excerptamedica.com/ciw-04ena/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=huang&topicselected=*&selection=ABSTRACT&qryStartRowDetail=1> [retrieved on 20091014] *
JOSTOCK T ET AL: "Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 289, no. 1-2, 1 June 2004 (2004-06-01), pages 65 - 80, XP004520880, ISSN: 0022-1759 *
SIEMEISTER G ET AL: "TWO INDEPENDENT MECHANISMS ESSENTIAL FOR TUMOR ANGIOGENESIS: INHIBITION OF HUMAN MELANOMA XENOGRAFT GROWTH BY INTERFERING WITH EITHER THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PATHWAY OR THE TIE-2 PATHWAY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 59, no. 13, 1 July 1999 (1999-07-01), pages 3185 - 3191, XP000971187, ISSN: 0008-5472 *
STEUKERS M ET AL: "Rapid kinetic-based screening of human Fab fragments", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 310, no. 1-2, 20 March 2006 (2006-03-20), pages 126 - 135, XP025158202, ISSN: 0022-1759, [retrieved on 20060320] *
TAKAGI HITOSHI ET AL: "Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JAN 2003, vol. 44, no. 1, January 2003 (2003-01-01), pages 393 - 402, XP002550533, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2006020706A2 (fr) 2006-02-23
AU2005272848A1 (en) 2006-02-23
JP2008532476A (ja) 2008-08-21
WO2006020706A3 (fr) 2006-10-12
EP1789451A2 (fr) 2007-05-30
CA2576886A1 (fr) 2006-02-23
AU2005272848A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1789451A4 (fr) Protéines de liaison au complexe tie
IL181005A0 (en) Polypeptide comprising binding domains
ZA200702004B (en) Binding domain fusion proteins
HK1103747A1 (en) Immunoglobulin binding hosm
ZA200703445B (en) Nanoparticulated whey proteins
IL182279A0 (en) Angiopoietin-2-specific binding agents
IL188671A0 (en) Il-6 binding proteins
GB0404187D0 (en) Binding agents
GB0423974D0 (en) Proteins
GB0410627D0 (en) Specific binding members
GB0417887D0 (en) Protein
GB0511799D0 (en) Protein binding ligands
GB0401882D0 (en) Protein
GB0416035D0 (en) Protein
GB0423002D0 (en) Proteins
GB0405885D0 (en) Proteins
GB0418666D0 (en) Proteins
GB0418248D0 (en) Proteins
GB0415161D0 (en) Proteins
GB0412570D0 (en) Proteins
GB0411678D0 (en) Proteins
GB0405643D0 (en) Proteins
GB0403979D0 (en) Protein
GB0414086D0 (en) Protein
GB0403742D0 (en) Protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOET, RENE

Inventor name: PIETERS, HENK

Inventor name: WOOD, CLIVE R.

Inventor name: HUFTON, SIMON E.

Inventor name: DRANSFIELD, DANIEL T.

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105646

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20091022BHEP

Ipc: C07K 16/28 20060101ALI20091022BHEP

Ipc: A61P 35/00 20060101ALI20091022BHEP

Ipc: A61K 39/395 20060101AFI20091022BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091102

17Q First examination report despatched

Effective date: 20100303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105646

Country of ref document: HK